Gatchina
Gatchina
Gatchina, Russia11 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR) | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Not stated | 2026-10-06 | NCT06472310 | |
| Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients | Infections, bronchial disorder, bronchitis, lung disorder, obstructive lung disease, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 3 | 2026-06-29 | NCT07650227 | |
| Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study | Uncontrolled Asthma | Recruiting | Not stated | 2026-04-20 | NCT06521229 | |
| The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients | Infections, Rhinosinusitis, nasal disorder, otorhinolaryngologic disease, paranasal sinus disorder, respiratory system disorder, respiratory tract infectious disorder, rhinitis, sinusitis | Recruiting | Phase 3 | 2026-03-16 | NCT06901297 | |
| Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years | Acute Respiratory Viral Infection | Recruiting | Phase 3 | 2026-03-13 | NCT06715891 | |
| Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children | Cough, Infections, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Signs and Symptoms, Respiratory, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 3 | 2026-02-13 | NCT07171099 | |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 3 | 2025-07-08 | NCT05751928 | |
| Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 1 / Phase 2 | 2025-06-13 | NCT06120582 | |
| A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-04-24 | NCT06185335 | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 3 | 2025-02-27 | NCT05732805 | |
| Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases | interstitial lung disease, lung disorder, respiratory system disorder | Recruiting | Phase 2 / Phase 3 | 2024-11-19 | NCT06440746 |